北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 眼科  > 期刊论文
学科主题: 临床医学
题名:
Bevacizumab for Neovascular Age-related Macular Degeneration in China
作者: Li, Xiaoxin1,2; Hu, Yonghua4; Sun, Xiaodong3; Zhang, Junjun5; Zhang, Maonian6; Neovasc Age-Related Macular Degene1
刊名: OPHTHALMOLOGY
发表日期: 2012-10-01
DOI: 10.1016/j.ophtha.2012.05.016
卷: 119, 期:10, 页:2087-2093
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Ophthalmology
研究领域[WOS]: Ophthalmology
关键词[WOS]: POLYPOIDAL CHOROIDAL VASCULOPATHY ; INTRAVITREAL INJECTION ; AVASTIN THERAPY ; RANIBIZUMAB ; PHARMACOKINETICS ; SAFETY
英文摘要:

Objective: To evaluate 2 different dosing regimens of intravitreal bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) patients in China.

Design: Multicenter, randomized, prospective, open-label clinical trial.

Participants: One hundred eighty-five patients with active neovascular AMD, exclusion of a macular scar, choroidal neovascularization not resulting from AMD, and polypoidal choroidal vasculopathy.

Intervention: Patients were assigned randomly to receive intravitreal injections of bevacizumab every 6 weeks for the first 3 injections followed by injections every 6 weeks (regimen A, n = 91) or every 12 weeks (regimen B, n = 94).

Main Outcome Measures: The primary outcome measure was a comparison of the mean change in visual acuity from baseline. The secondary outcome measure was a comparison of the proportion of patients with a change in visual acuity of 15 letters or more. Adverse events were monitored.

Results: One-hundred eighty five patients were enrolled. At 48 weeks, the increase in the mean visual acuity measurements from baseline were 12.58 letters in regimen A and 10.06 letters in regimen B (P = 0.288). At 48 weeks, the percentage of eyes losing fewer than 15 letters was 96.2% in regimen A and 93.9% in regimen B (P = 0.720). At 48 weeks, the median decrease in central retinal thickness measurements from baseline was 119 mu m in regimen A and 60 mu m in regimen B (P = 0.221). Adverse events during the 48 weeks included anterior chamber inflammation in 17 patients (18.7%) from regimen A and 9 patients (9.6%) from regimen B (P = 0.075). There were no other notable ocular adverse events in either group.

Conclusions: Intravitreal bevacizumab improved visual acuity and decreased macular thickness in patients with neovascular AMD when dosed either every 6 weeks or every 12 weeks after 3 doses given at 6-week intervals. Although there were no statistically significant differences between the 2 regimens, the results tended to favor the group dosed every 6 weeks (regimen A).

语种: 英语
所属项目编号: 2006BAI02B05
项目资助者: National Key Technology Research and Development Program in the 11th Five-Year Plan of China
WOS记录号: WOS:000310581900023
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/51511
Appears in Collections:北京大学第二临床医学院_眼科_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China
2.PLA, Dept Ophthalmol, Gen Hosp, Beijing, Peoples R China
3.Peking Univ, Dept Ophthalmol, Peoples Hosp, Beijing 100044, Peoples R China
4.Shanghai Jiao Tong Univ, Dept Ophthalmol, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China
5.Peking Univ, Sch Publ Hlth, Beijing 100044, Peoples R China
6.Sichuan Univ, Dept Ophthalmol, W China Hosp, Chengdu 610064, Peoples R China

Recommended Citation:
Li, Xiaoxin,Hu, Yonghua,Sun, Xiaodong,et al. Bevacizumab for Neovascular Age-related Macular Degeneration in China[J]. OPHTHALMOLOGY,2012,119(10):2087-2093.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Li, Xiaoxin]'s Articles
[Hu, Yonghua]'s Articles
[Sun, Xiaodong]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Li, Xiaoxin]‘s Articles
[Hu, Yonghua]‘s Articles
[Sun, Xiaodong]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace